Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, Fibrosis, Fibroblast, Lung attenuation, Pletysmography
Brief summary
Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown. The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.
Interventions
BIOLOGICALanalyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients
analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients
Sponsors
University Hospital, Bordeaux
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged more than 40 yr * Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery. * COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines. * Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex. * with a written informed consent
Exclusion criteria
* Subject without any social security or health insurance * Asthma, lung fibrosis or idiopathic pulmonary hypertension * Chronic viral infections (hepatitis, HIV) * Pregnant woman or breastfeeding * Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects. | Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0) |
Secondary
| Measure | Time frame |
|---|---|
| Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II | Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0) |
| Correlation between lung attenuation and the number of fibrocytes | Assessed one year after inclusion visit (i.e. surgery date =Day 0) |
| Correlation between plethysmography and the number of fibrocytes. | Assessed one year after inclusion visit (i.e. surgery date = Day 0) |
Countries
France
Contacts
STUDY_CHAIRNicholas MOORE, MD-PhD
University Hospital, Bordeaux
Outcome results
None listed